Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Carboplatin, and Amifostine in Endometrial Cancer
NCT00003127Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 1998
- Primary completion
- Apr 2003
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, carboplatin and amifostine in endometrial cancer (EC), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-Free Survival at 6 months. Started Feb 1998; status: completed.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatinamifostine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00003127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003127.